Dara L. Aisner, MD, PhD / Joshua Bauml, MD / Paul A. VanderLaan, MD, PhD - Precision Decisions in Genomic Testing and Targeted Treatment of NSCLC

Go online to PeerView.com/KQZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The management of patients with non–small cell lung cancer (NSCLC) is exemplary of precision medicine. Extensive and nuanced genomic profiling of NSCLC is essential to inform individualized treatment plans to optimize patient outcomes. Currently, there are seven different molecular alterations for which FDA-approved targeted therapies are available: EGFR, ALK, ROS1, BRAF V600E, NTRK, MET exon 14, and RET. With the growing complexity of the targeted therapeutic landscape of lung cancer, it is imperative that members of the multidisciplinary care team maintain best practices regarding genomic testing to effectively incorporate targeted therapies into clinical practice. This PeerView educational activity based on a recent web broadcast provides practical guidance for navigating the continuing wave of predictive genomic alterations and related matched therapies, uniting pathologists with oncologists and other multidisciplinary specialists to ensure that patients with genomically altered NSCLC receive appropriate testing and therapy. Upon completion of this activity, participants should be better able to: Discuss the expanding role and increasing importance of broad molecular testing for identifying patients with NSCLC who have therapeutically targetable molecular alterations, Describe the molecular alterations that are clinically relevant and therapeutically targetable in NSCLC, and the latest testing methods for identifying these alterations, Analyze data from clinical trials of precision therapies that target key molecular alterations in NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing to ensure that patients with NSCLC receive the most appropriate therapies in the context of clinical practice or clinical trials.